John Cox Sells 2,640 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Key Points

• Dyne Therapeutics CEO John Cox sold 2,640 shares at an average price of $13.41, reducing his stake to 199,539 shares valued at approximately $2.68 million.
• The company reported an earnings per share (EPS) of ($0.97) for the last quarter, exceeding analysts' expectations of ($0.99).
• Investment analysts have mixed ratings on Dyne Therapeutics, with an average rating of "Buy" and a consensus target price of $34.07.

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) CEO John Cox sold 2,640 shares of the business's stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $13.41, for a total transaction of $35,402.40. Following the completion of the transaction, the chief executive officer owned 199,539 shares of the company's stock, valued at $2,675,817.99. The trade was a 1.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

John Cox also recently made the following trade(s):

• On Monday, July 14th, John Cox bought 100,000 shares of Dyne Therapeutics stock. The stock was purchased at an average price of $9.11 per share, with a total value of $911,000.00.

Dyne Therapeutics Price Performance

DYN stock traded down $0.03 during trading on Friday, reaching $13.15. 2,028,284 shares of the company were exchanged, compared to its average volume of 2,196,233. The company has a 50-day moving average of $11.21 and a two-hundred day moving average of $11.12. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -3.41 and a beta of 1.10. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $37.08. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02. As a group, equities analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in DYN. Northern Trust Corp raised its stake in shares of Dyne Therapeutics by 7.7% during the fourth quarter. Northern Trust Corp now owns 777,013 shares of the company's stock worth $18,306,000 after acquiring an additional 55,511 shares in the last quarter. Comerica Bank raised its stake in shares of Dyne Therapeutics by 20,133.7% during the fourth quarter. Comerica Bank now owns 35,409 shares of the company's stock worth $834,000 after acquiring an additional 35,234 shares in the last quarter. Ameriprise Financial Inc. raised its stake in shares of Dyne Therapeutics by 3.2% during the fourth quarter. Ameriprise Financial Inc. now owns 219,635 shares of the company's stock worth $5,175,000 after acquiring an additional 6,735 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Dyne Therapeutics during the fourth quarter worth approximately $1,578,000. Finally, D. E. Shaw & Co. Inc. increased its stake in shares of Dyne Therapeutics by 83.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 133,772 shares of the company's stock worth $3,152,000 after buying an additional 60,732 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Stifel Nicolaus cut their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Royal Bank Of Canada lowered their price objective on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a report on Tuesday, July 29th. Sanford C. Bernstein assumed coverage on shares of Dyne Therapeutics in a report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price objective on the stock. Raymond James Financial upgraded shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and upped their price objective for the stock from $31.00 to $35.00 in a report on Monday, August 25th. Finally, Jones Trading assumed coverage on shares of Dyne Therapeutics in a report on Thursday, June 26th. They set a "buy" rating and a $30.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $34.07.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.